DDInter915 DDInter474
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosuria. Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents. Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April 2021.
Indacaterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dapagliflozin
Indacaterol {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Dapagliflozin
Indacaterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Canagliflozin
Canagliflozin {u} (Compound) resembles {v} (Compound) Dapagliflozin
Indacaterol {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Canagliflozin
Canagliflozin {u} (Compound) resembles {v} (Compound) Dapagliflozin
Indacaterol {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Simvastatin
Simvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dapagliflozin
Indacaterol {u} (Compound) causes {v} (Side Effect) Infestation
Infestation {u} (Side Effect) is caused by {v} (Compound) Regorafenib
Regorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dapagliflozin
Indacaterol {u} (Compound) causes {v} (Side Effect) Angina pectoris
Angina pectoris {u} (Side Effect) is caused by {v} (Compound) Moxifloxacin
Moxifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Indacaterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Indacaterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) interacts with {v} (Gene) UGT2B7
UGT2B7 {u} (Gene) is bound by {v} (Compound) Dapagliflozin
Indacaterol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Simvastatin
Simvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dapagliflozin
Indacaterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dapagliflozin (Compound)
Indacaterol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Dapagliflozin (Compound)
Indacaterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Canagliflozin (Compound) and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Indacaterol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Canagliflozin (Compound) and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Indacaterol (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Simvastatin (Compound) and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin
Indacaterol (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Regorafenib (Compound) and Regorafenib may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin
Indacaterol (Compound) causes Angina pectoris (Side Effect) and Angina pectoris (Side Effect) is caused by Moxifloxacin (Compound) and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Indacaterol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Indacaterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) interacts with UGT2B7 (Gene) and UGT2B7 (Gene) is bound by Dapagliflozin (Compound)
Indacaterol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Simvastatin (Compound) and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin